Vertex Pharmaceuticals' non-opioid drug, suzetrigine, showed little difference versus a placebo in reducing pain for lumbosacral radiculopathy, prompting FDA review for treating moderate-to-severe acute pain.
Vertex Pharmaceuticals' non-opioid drug demonstrated pain reduction in patients with lumbosacral radiculopathy but fell short of investor expectations, signaling continued interest in non-opioid treatment amid the opioid epidemic.
Reuters
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
"Unfortunately, when we reviewed the latest evidence, we found that taking vitamin D with or without calcium does not prevent falls or fractures in older adults."
In-depth exploration of public anger towards the American health care system throughout history, potential for change, and Hollywood's portrayal of health insurance-related events.